There should be higher taxes on executive compensation when CEOs like Michelle Miller continue to draw salaries from shareholder funds without delivering meaningful progress. It's time to shift toward true performance-based accountability. Executive rewards should be tied to measurable results—such as revenue growth, commercial milestones, and real value creation—not handed out for simply maintaining the status quo or outsourcing responsibilities.
Michelle Miller's decision to offload key responsibilities to C14—whether viewed as “Cute 14,” “Criminal 14,” “Clandestine 14,” or “Collaborator 14”—while approving retention fees from shareholder funds and collecting her own salary without producing outcomes, represents a serious failure of corporate governance. This kind of behaviour operates like a hidden cancer within the system, slowly draining shareholder value while escaping oversight.This isn’t just a leadership issue—it’s a structural flaw that regulators, lawmakers, and investors must urgently address. Tax policy should penalize passive, unearned executive pay and reward results-driven leadership. Biotron, under Michelle Miller, stands as a stark example of why these reforms are needed.
All posters' posts do matter. Please do Speak up, and let’s put an end to this cycle of manipulation—together.
- Forums
- ASX - By Stock
- BIT
- Helping Biotron to Do Better and Deliver Tangible Results: Shareholders Call for ASIC Action and Regulatory Scrutiny
BIT
biotron limited
Add to My Watchlist
0.00%
!
0.2¢

Helping Biotron to Do Better and Deliver Tangible Results: Shareholders Call for ASIC Action and Regulatory Scrutiny, page-35
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.2¢ | $9.297K | 4.648M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
58 | 36124677 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 18314543 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
58 | 36124677 | 0.002 |
32 | 65031001 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 18314543 | 26 |
0.004 | 12820969 | 17 |
0.005 | 6684000 | 5 |
0.006 | 1200000 | 2 |
0.007 | 1084188 | 2 |
Last trade - 14.18pm 26/06/2025 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online